Engineered endocrine objects tolerate hypoxia in macroencapsulation devices and enable subcutaneous engraftment in diabetic mice
Authors: K. Wang, K. Okada, M. Jin, J. Deng, B. Wang, J. A. Flanders, P. L. Tran, M. Lee, M. Ma
Abstract
Islet encapsulation has been pursued for decades as a potential immunosuppression-free transplantation strategy to treat type 1 diabetes (T1D). The encapsulation device protects islets from immune cell-contact mediated killing, but it also prevents vascular penetration and intra-islet vascularization, leading to poor mass transfer and islet central necrosis. In healthy pancreas, islets with sizes > ~40 m are vascularized while non-islet endocrine cell clusters below ~40 m exist without internal capillaries. Here, we developed scalable and reproducible engineered endocrine objects (EEOs) as small as ~47 m by mesh-induced fragmentation of native islets, followed by a recovery culture. Under hypoxic culture condition (1% O2 for 24 hours), EEOs showed enhanced viability of >90%, compared to 49% for the native islet control. With a flat, thin (0.5-mm-thick) alginate-based macroencapsulation device, rat EEOs at a marginal dose of 300 islet equivalents (IEQ) achieved glycemic control for over 5 weeks in the challenging, hypoxic subcutaneous space of immunocompetent diabetic mice. The engrafted mice displayed near-physiological glycemic profiles upon glucose challenge, and the retrieved EEOs showed enhanced viability with significantly reduced central necrosis compared with native islets. Overall, engineering hypoxia-resistance into cellular products mitigates intrinsic constraints of encapsulation devices, offering a promising strategy for convenient, immunosuppression-free subcutaneous islet transplantation.
The papers around it, by date and closeness
Higher is closer to this paper; left is older. Lines join papers close to each other: groups of lines are sub-topics. Select a point to see why it is there. Back to the summary of this paper
Papers around this one
Ranked by how close their title and abstract are to this paper’s. Select some to read them together.
Closest papers
-
Bridging scale-up to transplantation: pluripotent stem cell-derived pancreatic islet encapsulation in emulsion-generated high concentration alginate beadsArianna Castro Rojas, J. Brassard, Marie Billaud et al. · 2026 · bioRxiv · preprint, not peer reviewed · Not summarized yet
This study encapsulates stem-cell-derived islet-like clusters in concentrated alginate beads, addressing scale-up and graft survival rather than hypoxia-resistant engineered endocrine objects.
Abstract
Pluripotent stem cell-derived pancreatic islet-like cell clusters (SC-islets) have emerged as potential cellular therapy for type 1 diabetes. While SC-islets can theoretically be produced in bioreactors to meet transplantation needs of many recipients per batch, biomanufacturing and translational challenges remain. SC-islet can be cultured in suspension using stirred tank or vertical wheel bioreactors, but these can impart hydrodynamic damage and lead to cellular agglomeration, particularly upon scale-up. We previously described a robust emulsion-based process to encapsulate murine pancreatic beta cells in high-concentration alginate beads which improved graft survival in allogeneic recipien…
-
Safe host integration in islet tissue engineering for Type 1 Diabetes Mellitus: emerging technologies and a constraint-guided hybrid islet frameworkWallace Lung · 2026 · Journal of high school science · Not summarized yet
This review surveys islet tissue-engineering strategies and proposes a hybrid framework for balancing immune protection, oxygen delivery, fibrosis, and host integration.
Abstract
Type 1 diabetes mellitus (T1DM) results from autoimmune destruction of pancreatic β cells and requires lifelong insulin replacement. Islet transplantation can restore endogenous insulin secretion, but donor scarcity, immune rejection, early graft loss, inadequate oxygen delivery, and fibrosis limit its application. This review examines conventional and emerging islet tissue-engineering approaches and proposes a conceptual hybrid bio-artificial islet system (HBAIS). A heuristic constraint-exchange framework compares the functions gained from successive technological additions with their associated risks, overlapping benefits, and operational dependencies. The analysis identifies hypoimmune st…
-
Microgels Containing Protease Resistant CXCL12 and FasL Enable Long-term Allo-Islet Function Without Systemic Immunosuppression.F. Doğan, Assia El Babsiri, Esin Ozkan et al. · 2026 · Diabetes · Not summarized yet
This study uses FasL- and CXCL12-coated microgels to locally immunomodulate allogeneic islet grafts, reporting sustained function without systemic immunosuppression.
Abstract
ARTICLE HIGHLIGHTS Cotransplantation of allogeneic islets with microgels coated with streptavidin fused with Fas ligand and protease-resistant CXCL12 results in robust and sustained diabetes reversal for over 6 months in streptozotocin-induced diabetic mice and induces local immunomodulation, enhances Treg recruitment within the graft, and improves graft vascularization. This study addresses a critical challenge in cell transplantation, namely the need to develop technologies that enable local immunoprotection of the graft while eliminating the need for systemic immunosuppression. This combination microgel technology could offer a more favorable risk-benefit profile by reducing infection ris…
-
Combined B2M Knockout and Alginate Encapsulation Reduces Immune Rejection of iPSC-Derived Pancreatic ProgenitorsP. Ermakova, A. Barinova, Alexandra Y. Bogomolova et al. · 2026 · Cells · Not summarized yet
This study combines alginate encapsulation with B2M knockout to reduce immune rejection of iPSC-derived pancreatic progenitors.
Abstract
Allogeneic cell replacement therapy for diabetes using induced pluripotent stem cell (iPSC)-derived pancreatic progenitors (PPs) is currently limited by immune rejection. Alginate encapsulation and the genetic ablation of HLA-I via β2-microglobulin (B2M) knockout represent distinct strategies to reduce immune recognition and to protect the transplanted cells. We generated encapsulated B2M-knockout pancreatic progenitors (IPS-∆B2M-PPs) and evaluated their immunogenicity in vitro using each of: peripheral blood mononuclear cell (PBMC) co-culture, natural killer cell (NK cell) degranulation, T-cell activation, and rat macrophage adhesion. In vivo studies were also performed to assess capsule bi…
-
The capsule was never just a capsule: what islet encapsulation is for, now that immunoisolation is no longer its jobA. Citro, Lorenzo Piemonti · 2026 · Frontiers in Bioengineering and Biotechnology · Not summarized yet
This article argues that encapsulation must balance immune exclusion with transport, dose, host integration, durability, and retrieval, extending beyond the hypoxia constraint examined here.
Abstract
For more than four decades, islet encapsulation has been defined by a single objective: to immunoprotect transplanted cells while preserving glucose sensing and insulin delivery, thereby eliminating systemic immunosuppression. No passive device has yet achieved that objective with reproducible, durable and clinically meaningful efficacy. The central limitation is not simply the absence of an optimal polymer, but an over-constrained architecture in which immune exclusion, molecular transport, therapeutic cell dose, host integration, mechanical durability and retrieval must be solved simultaneously. The clinical contrast between sealed and vascularly accessible devices makes this coupling visi…
-
Graft Localized Immunomodulation with Rapamycin-Eluting PLGA Microparticles Promotes Murine Islet Allograft Survival and Induces Operational Tolerance.Jordan Wong, Purushothaman Kuppan, Nerea Cuesta-Gomez et al. · 2026 · American Journal of Transplantation · Not summarized yet
This study uses rapamycin-releasing PLGA microparticles to locally suppress immune responses and prolong murine islet allograft survival.
Abstract
Islet transplantation effectively restores physiologic glycemic regulation in a subset of individuals living with type 1 diabetes; however, lifelong systemic immunosuppression remains a major barrier to broader patient inclusion. Herein, we explored the use of a localized drug delivery system to preserve islet allograft function, circumventing systemic immunosuppression. Rapamycin (Rapa) was effectively encapsulated within poly(lactic-co-glycolic acid) microparticles (MP), which facilitated sustained and localized drug release to the islet grafts, modulating the immune environment and significantly prolonging allograft survival (p<0.05). Long-term outcomes were further enhanced when Rapa-MP …
-
Organotypic vascularization improves maturation of human stem cell-derived islets and restores normoglycemia in diabetic mice.Jing-Qiang Wang, A. Pélissier, Jeffrey S. H. Lin et al. · 2026 · Cell Stem Cell · cited 1 time · Not summarized yet
This study also addresses poor islet graft survival from inadequate oxygenation, using vascularized stem-cell-derived organoids to improve hypoxia resistance and restore normoglycemia.
Abstract
Human pluripotent stem cells-derived pancreatic islet organoids (PIOs) hold promise for treating type 1 diabetes, but poor post-transplant survival due to inadequate vascularization remains a major challenge. Here, we generated vascularized PIOs (VPIOs) by co-culturing PIOs with blood vessel organoids (BVOs), resulting in integrated structures with BVOs-derived capillary networks that penetrate into the islet structures. These blood vessels structurally exhibit fenestrations characteristic of islet-specific endothelium and carry a molecular signature of organotypic vasculature. β cells within the VPIOs display partially enhanced maturation and greater resistance to hypoxia and endoplasmic re…
-
High‐Density Dynamic Culture of Neonatal Porcine Islets Improves Islet Recovery and Function Post‐TransplantationSummer A. Helmi, Chelsea Castro, Soren Stachniak et al. · 2026 · Xenotransplantation · Not summarized yet
The study optimizes dynamic culture of neonatal porcine islets for scalable production and post-transplant function, rather than hypoxia-tolerant encapsulated grafts.
Abstract
ABSTRACT Introduction Type 1 diabetes (T1D) results from autoimmune destruction of pancreatic β‐cells, necessitating lifelong exogenous insulin therapy. Scalable β‐cell replacement strategies are needed to reproducibly increase ß cell production. Neonatal porcine islets (NPIs) are a promising xenogeneic source of ß cells; however, limited manufacturing scalability hinders clinical translation. This study optimizes a dynamic culture system to assess its potential for scalable NPIs production for clinical translation. Methods NPIs were cultured under three conditions: static suspension and dynamic suspension in a PBS Mini Vertical‐Wheel bioreactor at 4.5K (Bio 4.5) and 6.0K (Bio 6.0) NPIs/ml. …
Go further
How are these papers found?
We compare the title and abstract of this paper with those of every paper summarized on this site, and with the papers Semantic Scholar recommends, those it cites and those citing it (for a much-cited paper, its most recent citations and, from OpenAlex, the most cited ones). Among the prior work and the follow-ups, the papers that use each other in depth, a method it uses and the much-cited follow-ups come a little higher. The levels (very close, close, related) come from the similarity of the texts, not from a judgment of quality; * marks a paper without an abstract, compared by its title. The sentence under a paper is written by an AI from the two abstracts: check it in the papers. A paper marked not relevant by three readers leaves the list.
Updated on 16 November 2026.